Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Isis Pharmaceuticals Inc ISIS

Sector: Healthcare | Sub-Sector: Biotechnology

Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.
Price: $40.48 | Change: $-0.64 | %Change: -1.56%
Volume: 1.6m | Day High/Low: 41.660/40.220 | 52 Week High/Low: 62.66/22.25

Snapshot

Last Traded: October 22, 2014 07:13 Transaction Volume: 567,602
Open: $41.49 Previous Close: $41.12
Bid: $41.49 Ask: $41.63
Bid Size: 41 Ask Size: 100
Market Cap: $4.9b Shares Out: 117.7m
PE Ratio: N/A Dividend Yield: N/A
Scale: 1d 5d 3m 6m 1y 2y 5y
Type: Line Area OHLC

Advanced Charts

Latest Bullboard Posts

  • VP exercised options

    0 stars

    A vice president of Isis Pharmaceuticals Inc. exercised options for 12,200 shares of common stock and sold them under a prearranged...

    1 star


  • news and potential uptrend

    0 stars

    Isis Pharmaceuticals last week reported a sharp drop in its net loss for 2007 despite higher operating expenses as the company...

    1 star


  • Overview of the stock

    0 stars

    Here are some points to consider:1) Biotech industry is very volatile though ISIS stock prices started accelerating upwards in August and...

    0 stars


  • isis needs a kiss of life

    0 stars

    Maybe Tobin is the volunteer...trading on the 27th April,07 @ $10.22

    2.5 stars


  • Tobin Smith is pumping ISIS presently

    0 stars

    Wow, I can't believe that no one has left a message on this board since 2003. Toby Smith (Tobin) is calling this one a major buy-out...

    0 stars